Skip to main content
Springer Nature Link
Log in

Scales in Parkinson’s disease

  • WORKSH0P 2
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

The search for valid instruments to measure different domains of health disturbances becomes increasingly important for the assessment of Parkinson’s disease. The most widely used tool is the Unified Parkinson’s Disease Rating Scale (UPDRS) which was introduced in 1987 and is currently awaiting revision. In addition, a variety of instruments have been used to capture non-motor aspects of Parkinson’s disease but only a minority of these instruments has been validated for this particular disease condition. Measurements of quality of life are being incorporated into an increasing number of studies in order to reflect a more integral view of health and have contributed to a better understanding of the impact of disease and interventions. The International Classification of Functioning, Disability and Health introduced by the WHO in 2001 offers a multidimensional approach to human functioning and participation that can also be applied to the assessment of health status in PD. This workshop report will focus on the present state of clinimetry in PD and discuss future perspectives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chaudhuri KR, Martinez-Matín P, Schapira AHV et al. (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov Disord 21:916–923

    Article  PubMed  Google Scholar 

  2. Fahn S, Elton RL (1987) UPDRS program members Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson’s disease, vol. 2, Macmillanm Healthcare Information, Florham Park, pp 153–163

  3. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin Neuropharmacol 21:280–284

    PubMed  CAS  Google Scholar 

  4. Goetz CG, Stebbins GT, Chmura Ta, et al. (1995) Teaching tape for the motor section of the Unified Parkinson’s Disease Rating Scale. Mov Disord 10:263–266

    Article  PubMed  CAS  Google Scholar 

  5. Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D (2005) An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off. J Neural Transm 112(2):221–230

    Article  PubMed  CAS  Google Scholar 

  6. Korczyn AD, Brunt ER, Larsen JP, et al. (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease: the 053 Study Group. Neurology 53:364–370

    PubMed  CAS  Google Scholar 

  7. Marras C, Lang A, Krahn M, et al. (2004) Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Mov Disord 19:22–28

    Article  PubMed  Google Scholar 

  8. Mitchell SL, Harper DW, Bhalla R (2000) Patterns of outcome measurements in Parkinson’s disease clinical trials. Neuroepidemiology 19:100–108

    Article  PubMed  CAS  Google Scholar 

  9. Miyasaki JM, Shannon K, Voon V, et al. (2006) Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996–1002

    Article  PubMed  CAS  Google Scholar 

  10. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): Status and recommendations. Mov Disord 18:738–750

    Article  Google Scholar 

  11. Peto V, Jenkinson C (1999) Quality of life measures in Parkinson’s disease. In: Martín PM, Koller WC (eds) Quality of life in Parkinson’s disease. Masson S. A., Barcelona, pp 37–54

  12. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled doubleblind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245–255

    Article  PubMed  CAS  Google Scholar 

  13. Ramaker C, Marinus J, Stiggelbout, et al. (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 17:867–876

    Article  PubMed  Google Scholar 

  14. Rascol O, Brooks DJ, Brunt ER, et al. (1998) Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study—056 Study Group. Mov Disord 13:39–45

    Article  PubMed  CAS  Google Scholar 

  15. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K (2005) Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111(1):21–28

    Article  PubMed  CAS  Google Scholar 

  16. Richards M, Marder K, Cote L, et al. (1994) Interrater reliability of the Unified Parkinson’s Disease Rating Scale motor examination. Mov Disord 9:89–91

    Article  PubMed  CAS  Google Scholar 

  17. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69(3):308–312

    Article  PubMed  CAS  Google Scholar 

  18. Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15(6):1112–1118

    Article  PubMed  CAS  Google Scholar 

  19. Schrag A, Sampaio C, Counsell N, Poewe W (2006) Minimal clinically important change of the Unified Parkinson’s Disease Rating Scale. Mov Disord, (in press) DOI 10.1002/mds.20914

  20. World Health Organization (2002) Towards a Common Language for Function Disability and Health. Geneva. www.who.int/icf

Download references

Author information

Authors and Affiliations

  1. Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Paracelsusring 6a, 14547, Beelitz-Heilstätten, Germany

    Georg Ebersbach

  2. Städtisches Klinikum, Dpt. of Neurology, Hanau, Germany

    Horst Baas

  3. Parkinson-Center, Gertrudis-Klinik, Biskirchen, Germany

    Ilona Csoti

  4. Neurologist, Berlin, Germany

    Martina Müngersdorf

  5. Dept. of Neurology, Christian-Albrechts-Universität, Kiel, Germany

    Günther Deuschl

Authors
  1. Georg Ebersbach
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Horst Baas
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Ilona Csoti
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Martina Müngersdorf
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Günther Deuschl
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Georg Ebersbach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ebersbach, G., Baas, H., Csoti, I. et al. Scales in Parkinson’s disease. J Neurol 253 (Suppl 4), iv32–iv35 (2006). https://doi.org/10.1007/s00415-006-4008-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-006-4008-0

Key words